101% Original
Lowest Price
Free Shipping
Pause Tranexamic Acid Tablets
Pause tablets contain the active ingredient Tranexamic Acid, an anti-fibrinolytic medication designed to prevent and reduce bleeding. It works by slowing the breakdown of blood clots, providing effective support for conditions such as heavy menstrual bleeding, dysfunctional uterine bleeding, nosebleeds, tooth extractions, and post-surgical recovery involving oral, prostate, or bladder procedures.T
- Estimated Delivery : Up to 4 business days
- Free Shipping & Returns : On all orders over $200
Pause tablets contain the active ingredient Tranexamic Acid, an anti-fibrinolytic medication designed to prevent and reduce bleeding. It works by slowing the breakdown of blood clots, providing effective support for conditions such as heavy menstrual bleeding, dysfunctional uterine bleeding, nosebleeds, tooth extractions, and post-surgical recovery involving oral, prostate, or bladder procedures.
This medication must be taken in the dosage and duration prescribed by a qualified healthcare professional. Do not take this medication if you have a known allergy to Tranexamic Acid or any of its components.
| Active Ingredient | Tranexamic Acid |
| Product Type | Anti-fibrinolytic Tablet |
| Brand | Pause |
| Form | Tablet |
| Indication | Used to treat bleeding; helps to prevent or reduce bleeding in conditions like tooth removal, heavy periods, dysfunctional uterine bleeding, nosebleed, and in any oral, prostate, or bladder surgery. |
| Mechanism of Action | Anti-fibrinolytic; works by preventing the breakdown of clots which leads to the stoppage of bleeding. |
| Brand | Pause |
|---|
Be the first to review “Pause Tranexamic Acid Tablets”
Related products
-
VIDALISTA 40 MG TAB
Original price was: $200.$160Current price is: $160. -
Cenforce 150mg
Original price was: $200.$140Current price is: $140. -
-
Cenforce 200mg
Original price was: $220.$160Current price is: $160. -
suhagra 100 mg
Original price was: $180.$140Current price is: $140.
Reviews
There are no reviews yet.